Trade Mark Journal No.2026/018 1 May 2026

WO0000001913530 (5,44)

Office of origin: United States of America

Date of International Registration:3 March 2026
Date of designation in the UK: 3 March 2026
Image for mark 1913530 HAEBRIIO

International priority date claimed: 18 February 2026 (United States of America) (99658061)
Class 5
Pharmaceutical preparations for the treatment and prevention of rare and orphan diseases and disorders; pharmaceutical preparations for the treatment and prevention of hematological diseases and disorders; pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; pharmaceutical preparations for the treatment and prevention of genetic diseases and disorders; pharmaceutical preparations for the treatment and prevention of hereditary angioedema (HAE); pharmaceutical preparations for the treatment and prevention of bradykinin mediated angioedema; pharmaceutical preparations for the treatment and prevention of acquired angioedema.
Class 44
Providing medical information to healthcare providers and patients relating to hematological, inflammatory, genetic, and rare diseases and disorders; providing medical information, namely, providing healthcare providers and patients with information regarding clinical research, clinical trials and studies, disease management resources, and access to pharmaceuticals for the treatment and prevention of hereditary angioedema.

Pharvaris GmbH

Representative: Makiko Coffland Christensen O'Connor Johnson Kindness, 1201 Third Avenue, Suite 3600, Seattle WA 98101, UNITED STATES OF AMERICA